FDA HEAD GOES ANTI-VAX
The Highwire with Del Bigtree
The Highwire with Del Bigtree
4.9 • 3.4K Ratings
🗓️ 14 October 2023
⏱️ 12 minutes
🧾️ Download transcript
Summary
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | In May of this year, the FDA approved the first RSV vaccine |
| 0:05.0 | that's respiratory sensitional virus for people over 60. |
| 0:08.0 | And shortly after, here is the messaging you saw on your TV. |
| 0:11.0 | All right. |
| 0:12.0 | Flu and COVID shots are now available as are the new RSV vaccines. |
| 0:16.0 | It's time to avoid another triple-demic. |
| 0:18.0 | For the first time ever, have vaccines against all three |
| 0:21.0 | of the major viruses that spread this fall in winter. |
| 0:26.0 | You can be vaccinated against COVID-19, |
| 0:29.0 | influenza, and RSV, also known as respiratory sensitional virus. |
| 0:34.0 | With RSV, the CDC does say that co-administration |
| 0:37.0 | with other adult vaccines is acceptable. |
| 0:40.0 | The advantage is that you can get it taken care of in a single appointment. |
| 0:44.0 | They all can be given at the same time, |
| 0:46.0 | who in one arm, one in the other, |
| 0:48.0 | and then you would be good to go for the season. |
| 0:51.0 | We highly recommend, again, all three in the same visit |
| 0:53.0 | that way you're protected and geared up against this vaccine season. |
| 0:56.0 | All right. |
| 0:57.0 | Triple-ouch. |
| 0:58.0 | Okay. |
| 0:59.0 | Get them together. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Highwire with Del Bigtree, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Highwire with Del Bigtree and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.

